Microsoft
It is oriented towards research in life sciences, in a bid that seeks to bring OpenAI closer to the pharmaceutical and biotechnology sector.
A OpenAI announced a new research-oriented artificial intelligence model in life sciencesin a bet that seeks to bring the company closer to the sector pharmaceutical and from biotechnology.
It’s called GPT-Rosalind, named after British scientist Rosalind Franklin, and was designed to support work in biology, drug discovery and translational medicine.
OpenAI presents GPT-Rosalind as a trained model for “modern scientific work”based on published evidence, data, tools and experiences.
The company argues that progress in life sciences is not only hampered by the intrinsic complexity of biology, but also by long, fragmented and technically demanding research workflows, ranging from literature review to experiment design and analysis of results.
In this context, the promise of the new tool is help researchers move fastertesting more hypotheses and finding relationships that might otherwise go unnoticed.
According to OpenAI, the model will perform better in tasks that require reasoning about molecules, proteins, genes, biological pathways and processes associated with diseases.
The company also maintains that GPT-Rosalind is particularly effective in workflows with several steps, such as literature review, interpretation of the relationship between sequence and biological function, experimental planning and data analysis.
The idea, in practice, is to use AI not just as a writing or research engine, but as technical support for applied scientific reasoning.
The new investment is part of a broader strategy to bring OpenAI closer to the world of healthcare.
The company reports that the company is already working with organizations such as Amgen, Moderna, the Allen Institute and Thermo Fisher Scientific to apply the model to research and discovery processes.
Moderna chief executive Stéphane Bancel says the technology is already showing the ability to synthesize complex data and convert it into experimental workflows with the potential to accelerate research and development.
The announcement comes a few days after another initiative in the same sector. Last Tuesday, OpenAI revealed a partnership with Danish pharmaceutical company Novo Nordisk, aimed at accelerating the creation of new treatments.
